Table 1.
Baseline characteristics of the patients.
| AM group, n = 40 | Placebo group, n = 20 | |
|---|---|---|
| Women | 10 (25.0) | 11 (55.0) |
| Age, years | 75 (68–79) | 75 (58–81) |
| Body weight, kg | 64 (56–71) | 57 (51–66) |
| Lifestyle and medical history | ||
| Current smoking | 9 (23.0) | 3 (15.0) |
| Atrial fibrillation | 1 (2.5) | 0 (0.0) |
| Chronic heart failure | 0 (0.0) | 0 (0.0) |
| Hypertension | 37 (92.5) | 20 (100.0) |
| Diabetes mellitus | 11 (27.5) | 5 (25.0) |
| Dyslipidemia | 26 (65.0) | 16 (80.0) |
| Chronic kidney disease | 11 (27.5) | 3 (15.0) |
| Stroke/TIA prior to index stroke | 9 (22.5) | 2 (10.0) |
| Ischemic heart disease | 4 (10.0) | 2 (10.0) |
| Pre-morbid mRS | ||
| 0 | 31 (77.5) | 18 (90.0) |
| 1 | 6 (15.0) | 0 (0.0) |
| 2 | 3 (7.5) | 2 (10.0) |
| Laboratory data | ||
| White blood cell count,/μL | 6275 (5310–7755) | 6190 (5685–7305) |
| Hemoglobin, g/dL | 14.0 (13.3–14.8) | 14.3 (12.8–14.9) |
| Blood glucose, mg/dL | 122 (103–148) | 125 (110–170) |
| D-dimer,/μL | 0.9 (0.6–1.1) | 1.0 (0.6–1.4) |
| C-reactive protein, mg/dL | 0.09 (0.07–0.15) | 0.08 (0.04–0.14) |
| Time from onset/last known well, hour | ||
| To randomization | 9.2 (4.4–17.9) | 11.7 (7.3–19.0) |
| To investigational drug administration | 18.6 (9.6–22.2) | 20.4 (17.0–22.9) |
| Treatment | ||
| IV thrombolysis | 7 (18.0) | 3 (15.0) |
Data are presented as medians (interquartile ranges) or numbers (percentages).
AM, adrenomedullin; IV, intravenous; mRS, modified Rankin Scale; TIA, transient ischemic attack.